Teerlink JR, Diaz R, Felker GM, et al. - Given that in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial, omecamtiv mecarbil (a novel selective cardiac myosin activator) is being tested with respect to its safety and efficacy in patients with heart failure with reduced ejection fraction (HFrEF), researchers herein detail the baseline features of participants in GALACTIC‐HF as well as compared these with other contemporary trials. Randomization to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5, or 50 mg bid) was performed among adults with established HFrEF, New York Heart Association functional class ≥II, ejection fraction ≤ 35%, raised natriuretic peptides and either current hospitalization for heart failure or history of hospitalization/emergency department visit for heart failure within a year. According to findings, a well‐treated, high‐risk population from both inpatient and outpatient settings is enrolled in GALACTIC‐HF, which will afford a definitive assessment of the efficacy as well as the safety of this novel therapy, also informing its potential future implementation.